Abstract C065: Impact of polyethylene glycol bowel preparation on the gut microbiome composition and response to immune checkpoint inhibition

Abstract Introduction: The gut microbiome has emerged as a biomarker of response to immune checkpoint inhibitor (ICI). Fecal microbiota transplantation (FMT) in combination with ICI has shown therapeutic promise with 6 positive trials. Polyethylene glycol (PEG)–based bowel preparation is routinely performed prior to FMT. However, its impact on gut microbiome and potential influence on ICI outcomes are unknown, creating uncertainty on whether placebo arms should receive bowel preparation. Methods: We conducted a prospective trial in 20 healthy volunteers (HV) (NCT06831539) who consumed 4L of PEG, and fecal samples were collected at baseline and multiple timepoints post-PEG. Shotgun metagenomics was analyzed using the MetaPhlAn4 and findings were validated by qPCR. To model PEG-induced gut microbiome disruption, mice were transiently exposed to 50% or 75% PEG for 12 days with longitudinal stool collection. To assess the effect of PEG-induced dysbiosis on ICI efficacy, tumor-bearing mice (MCA-205 or HKP1) were treated with anti-PD-1 or isotype under water, PEG, or antibiotics exposure. Tumor-infiltrating lymphocytes (TILs) were profiled by flow cytometry, and colonic tight-junction integrity was assessed using RT-qPCR and immunofluorescence. Results: In the HV cohort, median age was 30 years and 5 (25%) were male. Metagenomics revealed a transient decrease in α diversity (Shannon index, p=0.07) at the time of bowel preparation and most patients recovered α and β diversity at 3 days post-PEG, confirmed by qPCR. At 3 days post-PEG, 4 HV (20%) experienced a decrease in α diversity and change in β diversity from baseline, with complete recovery at 1 week except for one HV. All participants fully recovered at the 2 week timepoint. In mice, transient exposure to PEG led to recovery of α and β diversity at 3 days, and did not interfere with anti-PD-1 response. Conversely, continuous exposure to PEG significantly and persistently altered the gut microbiome composition, and impaired anti-PD-1 response in MCA-205 and HKP1 tumor-bearing mice, with reduced memory CD8+ and ICOS+CD4+ T-cell populations in TILs of PEG-treated mice compared to water controls. PEG significantly decreased colonic tight junction protein expression, though unlike antibiotics the detrimental effect of PEG on ICI response was independent of MAdCAM-1. To examine the relevance of prolonged PEG exposure in patients, clinical data from 197 advanced NSCLC patients showed that 17g PEG was associated with shorter progression-free survival to ICI (5.5 vs 11 months, HR 1.5, p=0.03), confirmed in multivariable analysis (HR 1.8, p=0.005). Conclusion: PEG bowel preparation causes transient disruption of the gut microbiome, with most healthy volunteers showing rapid recovery. However, a subset did not return to baseline by day 3, highlighting the need for caution when using PEG in placebo arms of microbiome-focused RCTs, specifically, monitoring the gut microbiome post-PEG, and allowing for adequate recovery prior to ICI start. Citation Format: Yongjia Hu, Alyse Filin, Diana Rusu, Sebastien Hunter, Diogjena Prifti, Xiaojing Dong, Meriem Messaoudene, Mayra Ponce, Jade Maillou, Wiam Belkaid, Julie Malo, Bertrand Routy, Arielle Elkrief. Impact of polyethylene glycol bowel preparation on the gut microbiome composition and response to immune checkpoint inhibition [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr C065.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Research
Published
2026-02-18
DOI
https://doi.org/10.1158/2326-6074.io2026-c065
Primary Topic
Clostridium difficile and Clostridium perfringens research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract C065: Impact of polyethylene glycol bowel preparation on the gut microbiome composition and response to immune checkpoint inhibition

Sarah Hunter, Wiam Belkaïd, Yongjia Hu, Meriem Messaoudene et al.
Cancer Immunology Research
Clostridium difficile and Clostridium perfringens research
article

Abstract C065: Impact of polyethylene glycol bowel preparation on the gut microbiome composition and response to immune checkpoint inhibition

Sarah Hunter, Wiam Belkaïd, Yongjia Hu, Meriem Messaoudene, B. Routy, Mayra Ponce, Diogjena Katerina Prifti, Jade Maillou, Julie Malo, Alysé Filin, Arielle Elkrief, Diana Rusu, Xiaojing Dong
article en

Abstract

Abstract Introduction: The gut microbiome has emerged as a biomarker of response to immune checkpoint inhibitor (ICI). Fecal microbiota transplantation (FMT) in combination with ICI has shown therapeutic promise with 6 positive trials. Polyethylene glycol (PEG)–based bowel preparation is routinely performed prior to FMT. However, its impact on gut microbiome and potential influence on ICI outcomes are unknown, creating uncertainty on whether placebo arms should receive bowel preparation. Methods: We conducted a prospective trial in 20 healthy volunteers (HV) (NCT06831539) who consumed 4L of PEG, and fecal samples were collected at baseline and multiple timepoints post-PEG. Shotgun metagenomics was analyzed using the MetaPhlAn4 and findings were validated by qPCR. To model PEG-induced gut microbiome disruption, mice were transiently exposed to 50% or 75% PEG for 12 days with longitudinal stool collection. To assess the effect of PEG-induced dysbiosis on ICI efficacy, tumor-bearing mice (MCA-205 or HKP1) were treated with anti-PD-1 or isotype under water, PEG, or antibiotics exposure. Tumor-infiltrating lymphocytes (TILs) were profiled by flow cytometry, and colonic tight-junction integrity was assessed using RT-qPCR and immunofluorescence. Results: In the HV cohort, median age was 30 years and 5 (25%) were male. Metagenomics revealed a transient decrease in α diversity (Shannon index, p=0.07) at the time of bowel preparation and most patients recovered α and β diversity at 3 days post-PEG, confirmed by qPCR. At 3 days post-PEG, 4 HV (20%) experienced a decrease in α diversity and change in β diversity from baseline, with complete recovery at 1 week except for one HV. All participants fully recovered at the 2 week timepoint. In mice, transient exposure to PEG led to recovery of α and β diversity at 3 days, and did not interfere with anti-PD-1 response. Conversely, continuous exposure to PEG significantly and persistently altered the gut microbiome composition, and impaired anti-PD-1 response in MCA-205 and HKP1 tumor-bearing mice, with reduced memory CD8+ and ICOS+CD4+ T-cell populations in TILs of PEG-treated mice compared to water controls. PEG significantly decreased colonic tight junction protein expression, though unlike antibiotics the detrimental effect of PEG on ICI response was independent of MAdCAM-1. To examine the relevance of prolonged PEG exposure in patients, clinical data from 197 advanced NSCLC patients showed that 17g PEG was associated with shorter progression-free survival to ICI (5.5 vs 11 months, HR 1.5, p=0.03), confirmed in multivariable analysis (HR 1.8, p=0.005). Conclusion: PEG bowel preparation causes transient disruption of the gut microbiome, with most healthy volunteers showing rapid recovery. However, a subset did not return to baseline by day 3, highlighting the need for caution when using PEG in placebo arms of microbiome-focused RCTs, specifically, monitoring the gut microbiome post-PEG, and allowing for adequate recovery prior to ICI start. Citation Format: Yongjia Hu, Alyse Filin, Diana Rusu, Sebastien Hunter, Diogjena Prifti, Xiaojing Dong, Meriem Messaoudene, Mayra Ponce, Jade Maillou, Wiam Belkaid, Julie Malo, Bertrand Routy, Arielle Elkrief. Impact of polyethylene glycol bowel preparation on the gut microbiome composition and response to immune checkpoint inhibition [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr C065.

Cancer Immunology ResearchVol. 14(2_Supplement)
Centre Hospitalier de l’Université de Montréal (CA)
Good health and well-being
Openalex Percentile: Top 51%
Clostridium difficile and Clostridium perfringens research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.